A Pilot Study of 64-Cu Labeled Brain PET/MRI for MM-302, a Novel HER2 Targeting Agent, in Advanced HER2+ Cancer With Brain Metastases
| Registry | NCT02735798 |
|---|---|
| Status | Withdrawn - The study was not started due to the sponsor choosing to not fund the trial. |
| Phase | Early Phase 1 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Sponsor | Pamela Munster (Other) |
| Conditions | Brain Metastases, Documented Her2 Overexpression, Advanced Solid Tumor, Neurologically Stable |
| Interventions | MM-302, Trastuzumab (Drug) |
| Dates | start 2016-04-01, primary completion 2017-06-01 (estimated), completion 2018-06-01 (estimated), first posted 2016-04-13, last updated 2017-05-04 |
Related Papers Related Patents Related Grants Related Experts
All trials for Brain Metastases All trials for Documented Her2 Overexpression All trials of MM-302 All trials of Trastuzumab
This is a single arm pilot study of 64Cu-MM-302 and unlabeled MM-302 in combination with trastuzumab in 10 patients with advanced HER2+ cancer with new or progressive brain metastases. Patients will receive standard imaging at baseline, including FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at the recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) three hours after unlabeled dose of MM-302. Integrated MR/PET imaging of the brain and whole body will be performed at two time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive subsequent doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (either in the brain or systemically) or unacceptable toxicity, whichever occurs soonest. MR brain imaging and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Single Arm Study - Arm 1 | Experimental | Drug: MM-302; Drug: Trastuzumab | 10 patients will receive standard imaging at baseline, incl. FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) 3 hours after unlabeled dose of MM-302. Integrated MR/PET imaging of brain and whole body will be performed at 2 time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (in brain or systemically) or unacceptable toxicity, whichever occurs soonest. MRI and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Histologically confirmed advanced solid tumor malignancy with documented HER2 overexpression or gene amplification on prior archival tumor tissue by CLIA-certified laboratory * New or progressive brain metastases with at least one metastasis measuring ≥ 1 cm in longest diameter on MR imaging * Patients may have extra-cranial metastatic disease but this is not required for study entry * Neurologically stable as defined by ALL of the following: * Stable or decreasing dose of steroids and anti-convulsants for at least 14 days prior to study entry * No clinically significant mass effect, midline shift, or impending herniation on baseline brain imaging * No significant focal neurologic signs and/or symptoms which would necessitate radiation therapy or surgical decompression in the judgment of the treating clinician * Prior radiation therapy for treatment of brain metastases completed at least 4 weeks prior to study entry * Prior radiation therapy for brain metastases allowed but must have been at least 4 weeks prior to study entry and follow up imaging is not consistent with pseudoprogression in the judgment of treating clinician * Patients must be ambulatory with ECOG performance status of 0 - 1. * Adequate organ function, including absolute neutrophil count (ANC) ≥1500 cells/uL, hemoglobin ≥9.0 gm/dL, platelets ≥100,000 cells/uL, estimated creatinine clearance ≥50 mL/min (by the Cockcroft Gault equation), bilirubin <1.5x ULN (unless Gilbert's is suspected), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <1.5x ULN (< 3x ULN if known liver metastases). * Ejection fraction as assessed by MUGA or echocardiogram > 50% * Prior cumulative doxorubicin exposure < 300 mg/m2 (or epirubicin equivalent) * Last dose of prior systemic anti-cancer therapy administered at least 5 half-lives or 4 weeks prior to study entry, whichever is shorter * No contra-indications to MRI (e.g. pacemaker, aneurysm clips, severe claustrophobia) * Patients will sign a study-specific IRB-approved consent prior to study entry. Patients must be able and willing to consent and undergo study procedures. * Age ≥18 years old Exclusion Criteria: * Prior treatment with MM-302 * Patients with any class of New York Heart Association (NYHA) CHF or heart failure with preserved ejection fraction (HFPEF) * Patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months * Patients with persistently uncontrolled hypertension (systolic BP > 160 mm Hg or diastolic BP > 100 mm Hg) despite optimal medical therapy * Patients with known unstable angina pectoris * Patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia) * Patients with a prolonged QTc interval (≥ 450 ms) * Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity * Patients with a history of LVEF decline to below 50% during or after prior trastuzumab/lapatinib or other HER2 directed therapy. * Current dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy. * Any serious and/or unstable pre-existing medical, psychiatric, or other medical condition that could interfere with subject's safety, provision of informed consent, or compliance with study procedures * Presence of leptomeningeal disease in the absence of parenchymal brain metastases